TherapyEdge helps to not only capture but also to integrate all patient data and particular decision support modules to access critical medical data that is coupled to knowledge databases and specific expert algorithm meant for personalised medicine and treatment decisions.
ABL Research and Development vice-president Ronan Boulme said this is a significant milestone for the company as it indicates its commitment to meeting the quality and safety standards required by the international healthcare marketplace.
"We have received an incredible level of interest in bringing our applications to Europe and other territories, and we can now move forward with our expansion plans," Boulme added.
The CE Mark certification has been given for ABL’s three core offerings: TherapyEdge, ViroScore and DeepChek.
ViroScore and DeepChek received the CE Mark for in-vitro diagnostic use earlier in 2012. The European medical device directives were revised in February 2012.
